Format

Send to

Choose Destination
Clin Med Insights Cardiol. 2015 Dec 3;9:113-7. doi: 10.4137/CMC.S26624. eCollection 2015.

Low High-Density Lipoprotein and Risk of Myocardial Infarction.

Author information

1
University of California, Riverside, School of Medicine, Riverside, CA, USA. ; Riverside Medical Clinic, Riverside, CA, USA.

Abstract

Low HDL is an independent risk factor for myocardial infarction. This paper reviews our current understanding of HDL, HDL structure and function, HDL subclasses, the relationship of low HDL with myocardial infarction, HDL targeted therapy, and clinical trials and studies. Furthermore potential new agents, such as alirocumab (praluent) and evolocumab (repatha) are discussed.

KEYWORDS:

AIM-HIGH; Apo; ApoA-I; ApoA-II; Biosynthesis; CETP; HDL; HDL subclass; HDL-C; HP2-THRIVE; LDL; LIPG; ODYSSEY; OSLER; PAF-AH; PCSK; PCSK9; PON1; TRIUMPH; acetylhydrolase; alirocumab; apolipoprotein; atheroprotective; cholesterol; convertase; dyslipidemia; elimination; endothelial lipase gene; evolocumab; heart attack; high density lipoprotein; hyperlipidemia; kexin; low HDL; monoclonal antibody; myocardial infarction; niacin; paraoxonase-1; platelet activating factor; praluent; proprotein; repatha; review; statin; storage; sublisin

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center